Long‐term outcomes of children with extracutaneous juvenile xanthogranulomas in Japan
Authors:
- Akira MorimotoAMAkira Morimoto
- Takeshi AsanoTATakeshi Asano
- Yuhki KogaYKYuhki Koga
- Yozo NakazawaYNYozo Nakazawa
- Histiocytosis Study Group of the Japanese Society of Pediatric Hematology/OncologyHHHistiocytosis Study Group of the Japanese Society of Pediatric Hematology/Oncology
- 8 May 2020
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 67 (7) , e28381
Abstract
Background: Juvenile xanthogranuloma (JXG) is the most common non‐Langerhans cell histiocytosis in children. The mortality and morbidity of JXG with extracutaneous lesions remain unclear.Methods: Data of patients aged < 18 years who were diagnosed with JXG between 2001 and 2010 were retrospectively collected through a nationwide survey.Results: Twenty patients (11 male and nine female) had extracutaneous lesions. The median observation time was 10 years (range, 0‐17). Six patients presented with symptoms at birth. The median age at diagnosis was 8.5 months (range, 0 month‐13 years). Fifteen patients underwent treatment for JXG, including chemotherapy (n = 11), and five did not receive treatment. All patients except one survived; 17 were disease‐free and two survived with disease. One newborn‐onset patient with liver, spleen, and bone marrow involvement died of the disease. Permanent sequelae included central diabetes insipidus, growth hormone deficiency, and panhypopituitarism detected at diagnosis in three, one, and two patients, respectively. Four patients had visual impairment (optic nerve compression and intraocular invasion in two each), three had epilepsy, one had mental retardation, and one had a skin scar. Eight patients who had intracranial lesions were older at diagnosis, and had a higher frequency of disease‐related comorbidities and permanent sequelae than those without intracranial involvement.Conclusions: Patients with extracutaneous JXG had good outcomes, although those with intracranial lesions had serious permanent sequelae. Effective and safe treatment regimens for patients with intracranial JXG need to be developed.Keywords
This publication has 28 references indexed in Scilit:
- Recent advances in Langerhans cell histiocytosisPediatrics International, 2014
- Severe persistent bone marrow failure following therapy with 2‐chlorodeoxyadenosine for relapsing juvenile xanthogranuloma of the brainPediatric Blood & Cancer, 2011
- Congenital systemic juvenile xanthogranuloma with placental lesionPediatrics International, 2009
- Systemic Juvenile Xanthogranuloma with Fatal OutcomePediatric Dermatology, 2009
- Juvenile xanthogranuloma in a child with previously unsuspected neurofibromatosis type 1 and juvenile myelomonocytic leukemiaPediatric Blood & Cancer, 2009
- Treatment of juvenile xanthogranulomaPediatric Blood & Cancer, 2008
- Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosisCancer, 2006
- Juvenile Xanthogranuloma in Childhood and AdolescenceAmerican Journal of Surgical Pathology, 2005
- Endocrine involvement in pediatric-onset langerhans' cell histiocytosis: a population-based studyThe Journal of Pediatrics, 2004
- Juvenile xanthogranuloma: Forms of systemic disease and their clinical implicationsThe Journal of Pediatrics, 1996